Supernus inks Navitor pact, betting up to $475M on depression candidate April 22, 2020 By Michael Fitzhugh No Comments Supernus Pharmaceuticals Inc. has struck an agreement with privately held Navitor Pharmaceuticals Inc. to run a joint phase II program for Navitor's mTORC1 activator, NV-5138, in treatment-resistant depression (TRD).Read More